<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851252</url>
  </required_header>
  <id_info>
    <org_study_id>HVPG-BB-EX-513</org_study_id>
    <nct_id>NCT01851252</nct_id>
  </id_info>
  <brief_title>MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy</brief_title>
  <official_title>Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect on the (carbon 13
      labelled(13C)-Methacetin Breath Test (MBT) of i.v. propranolol, a non-selective beta blocker
      (NSBB) following initial administration and after chronic use of each of these agents. The
      correlation of the MBT with Hepatic Venous Pressure Gradient (HVPG) measurement before and
      after treatment will be assessed. Additionally, the MBT measurements following 60 days of
      therapy will be compared to the first MBT measurement and to the second MBT measurement, post
      HVPG. Each patient's subsequent MBT measurement will be compared to his previous MBT results
      in order to determine his/her response to therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variceal bleeding is a life threatening complication of cirrhosis, which still carries a high
      mortality. Non selective beta-adrenergic blockers are effective at preventing first time
      variceal bleeding and re-bleeding. The efficacy of these drugs depends on the magnitude of
      reduction in portal pressure after administration, which varies widely between patients.
      Studies have shown that a reduction in portal pressure (as measured by HVPG) to 20% from
      baseline or to values ≤ 12 millimeters of mercury (mmHg) is associated with a low residual
      risk of bleeding . Patients with such a reduction are considered to be &quot;responders&quot; to beta
      blocker (BB) therapy. Unfortunately, a significant percentage of patients do not respond to
      therapy and need to be prescribed to an alternative therapy. The clinical application of this
      observation is limited since it requires a repeated HVPG measurement,which is not feasible in
      most cases. A non-invasive breath test that can assess portal pressure in correlation to HVPG
      and allow efficient management of patients at risk, could be very useful.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between HVPG and MBT and their changes following the i.v. administration of Propranolol</measure>
    <time_frame>7 days</time_frame>
    <description>MBT baseline measure will be measured within a week before the anticipated HVPG procedure, but not on the same day. The HVPG will be measured approximately 30 minutes after i.v. propanolol is given and the MBT will be performed approximately one hour later.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The changes between MBT at baseline level and after chronic treatment in Propranolol</measure>
    <time_frame>7 days</time_frame>
    <description>MBT baseline measure will be measured within a week before the anticipated HVPG procedure, but not on the same day. The HVPG will be measured approximately 30 minutes after i.v. propanolol is given and the MBT will be performed approximately one hour later.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MBT correlation to clinical events after 2 month of treatment</measure>
    <time_frame>67 days</time_frame>
    <description>The MBT will be performed on subjects again after 60 days of oral beta blocker treatment and its results will be compared to previous MBT values.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Chronic Liver Disease</condition>
  <condition>Cirrhosis</condition>
  <condition>Esophageal Varices</condition>
  <condition>Portal Hypertension</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Methacetin (for BT) before / after Propanolol treatment.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Methacetin (with Breath testing device)</intervention_name>
    <description>The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.</description>
    <arm_group_label>Methacetin (for BT) before / after Propanolol treatment.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -&gt; 18 years old (M/F)

        -Diagnosis of cirrhosis: i. By liver biopsy ii. Or strong suspicion of cirrhosis by
        accepted criteria for the clinical diagnosis of cirrhosis (e.g. peripheral edema or
        varices, palpable hard left lobe of the liver, small right lobe span or palpable
        splenomegaly), and/or radiological evidence of cirrhosis (by abdominal US, CT, or MRI,
        showing a nodular liver and/or portosystemic collaterals with portal vein patency and/or
        ascites and/or splenomegaly, and/or colloid shift on a colloid-isotope liver-spleen scan),
        and/or laboratory variables (platelets &lt;100,000/mm3, albumin&lt; 3.5g/dL, or international
        normalized ratio (INR)&gt;1.3) iii. Presence of esophageal varices (without previous variceal
        bleeding episode) or HVPG≥10mmHg 12mmHg from previous testing.

        -Has been scheduled for hemodynamic study testing, including response to acute therapy.-

        Exclusion Criteria:

          -  Patients already receiving beta blockers

          -  Hepatocellular carcinoma

          -  Portal vein thrombosis

          -  Contraindications to non-selective beta blocker Propanolol

          -  Cholestatic liver disease

          -  Severe heart, pulmonary or renal disease.

          -  Patient has previous surgical bypass surgery for morbid obesity

          -  Patient has extensive small bowel resection

          -  Any major surgery in the past 3 months.

          -  Patient is a recipient of any organ transplant

          -  Patient allergic to acetaminophen.

          -  Patients who are taking hepatotoxic drugs

          -  Patient, based on the opinion of the investigator, should not be enrolled into this
             study.

          -  Patients unable or unwilling to sign informed consent

          -  Patients that are participating in other clinical trials evaluating experimental
             treatments or procedures or have participated in a clinical trial in the past 3
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eyal Ashkenazi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.ehow.com/how_7539959_measure-pressure-portal-vein.html</url>
    <description>How to measure the pressure of the portal vein</description>
  </link>
  <reference>
    <citation>Chalasani N, Kahi C, Francois F, Pinto A, Marathe A, Bini EJ, Pandya P, Sitaraman S, Shen J. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol. 2003 Mar;98(3):653-9.</citation>
    <PMID>12650802</PMID>
  </reference>
  <reference>
    <citation>Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004 Sep;40(3):652-9.</citation>
    <PMID>15349904</PMID>
  </reference>
  <reference>
    <citation>Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. Hepatology. 2006 Mar;43(3):500-5.</citation>
    <PMID>16496319</PMID>
  </reference>
  <reference>
    <citation>de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005 Jul;43(1):167-76. Erratum in: J Hepatol. 2005 Sep;43(3):547.</citation>
    <PMID>15925423</PMID>
  </reference>
  <reference>
    <citation>Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007 Aug;133(2):481-8. Epub 2007 May 21.</citation>
    <PMID>17681169</PMID>
  </reference>
  <reference>
    <citation>Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003 Apr;37(4):902-8.</citation>
    <PMID>12668985</PMID>
  </reference>
  <reference>
    <citation>Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006 Mar;101(3):506-12.</citation>
    <PMID>16542287</PMID>
  </reference>
  <reference>
    <citation>Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990 Nov;99(5):1401-7.</citation>
    <PMID>2210246</PMID>
  </reference>
  <reference>
    <citation>Feu F, García-Pagán JC, Bosch J, Luca A, Terés J, Escorsell A, Rodés J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995 Oct 21;346(8982):1056-9.</citation>
    <PMID>7564785</PMID>
  </reference>
  <reference>
    <citation>Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000 Nov;32(5):930-4.</citation>
    <PMID>11050041</PMID>
  </reference>
  <reference>
    <citation>Bureau C, Péron JM, Alric L, Morales J, Sanchez J, Barange K, Payen JL, Vinel JP. &quot;A La Carte&quot; treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology. 2002 Dec;36(6):1361-6.</citation>
    <PMID>12447860</PMID>
  </reference>
  <reference>
    <citation>Bosch J, Groszmann RJ. Measurement of azygos venous blood flow by a continuous thermal dilution technique: an index of blood flow through gastroesophageal collaterals in cirrhosis. Hepatology. 1984 May-Jun;4(3):424-9.</citation>
    <PMID>6609870</PMID>
  </reference>
  <reference>
    <citation>Escorsell A, Bordas JM, Castañeda B, Llach J, García-Pagán JC, Rodés J, Bosch J. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology. 2000 May;31(5):1061-7.</citation>
    <PMID>10796880</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, Morse SS, Alberts JL. Short-term effects of propranolol on portal venous pressure. Hepatology. 1986 Jan-Feb;6(1):101-6.</citation>
    <PMID>3943775</PMID>
  </reference>
  <reference>
    <citation>La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagán JC, Bosch J. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol. 2009 Aug;51(2):279-87. doi: 10.1016/j.jhep.2009.04.015. Epub 2009 May 24.</citation>
    <PMID>19501930</PMID>
  </reference>
  <reference>
    <citation>Valla D, Jiron MI, Poynard T, Braillon A, Lebrec D. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol. 1987 Oct;5(2):144-8.</citation>
    <PMID>3500973</PMID>
  </reference>
  <reference>
    <citation>Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Aliment Pharmacol Ther. 2005 Sep 1;22(5):433-9.</citation>
    <PMID>16128681</PMID>
  </reference>
  <reference>
    <citation>Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology. 1987 Jul-Aug;7(4):648-53.</citation>
    <PMID>3610045</PMID>
  </reference>
  <reference>
    <citation>Bañares R, Moitinho E, Matilla A, García-Pagán JC, Lampreave JL, Piera C, Abraldes JG, De Diego A, Albillos A, Bosch J. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002 Dec;36(6):1367-73.</citation>
    <PMID>12447861</PMID>
  </reference>
  <reference>
    <citation>Braden B, Faust D, Sarrazin U, Zeuzem S, Dietrich CF, Caspary WF, Sarrazin C. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2005 Jan 15;21(2):179-85.</citation>
    <PMID>15679768</PMID>
  </reference>
  <reference>
    <citation>Festi D, Capodicasa S, Sandri L, Colaiocco-Ferrante L, Staniscia T, Vitacolonna E, Vestito A, Simoni P, Mazzella G, Portincasa P, Roda E, Colecchia A. Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels. World J Gastroenterol. 2005 Jan 7;11(1):142-8.</citation>
    <PMID>15609414</PMID>
  </reference>
  <reference>
    <citation>Goetze O, Selzner N, Fruehauf H, Fried M, Gerlach T, Mullhaupt B. 13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry. Aliment Pharmacol Ther. 2007 Jul 15;26(2):305-11.</citation>
    <PMID>17593076</PMID>
  </reference>
  <reference>
    <citation>de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000 Nov;33(5):846-52.</citation>
    <PMID>11097497</PMID>
  </reference>
  <reference>
    <citation>Bosch J, Garcia-Pagán JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis. 2006 Nov;26(4):348-62. Review.</citation>
    <PMID>17051449</PMID>
  </reference>
  <reference>
    <citation>Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004 Feb;39(2):280-2. Review.</citation>
    <PMID>14767976</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhotics</keyword>
  <keyword>Esophageal varices</keyword>
  <keyword>Portal Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

